Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02971969 · ClinicalTrials.gov registry record
Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B
A clinical trial of Hemophilia B, sponsored by Ultragenyx Pharmaceutical.
- Completed
- Registry status
- 6
- Enrollment target
- 5
- Study locations
NCT02971969 is a study of Hemophilia B that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 6 participants, below the 96-participant average among 20 other Hemophilia B trials with a reported enrollment target (94% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT02971969, a study of Hemophilia B, has completed, sponsored by Ultragenyx Pharmaceutical.
- COMPLETED
- Registry status
- 6 participants
- Enrollment target
- 5
- Study locations
Study Summary
A long-term follow-up study to evaluate the safety, tolerability, and efficacy of DTX101 in adult males with moderate/severe to severe hemophilia B.
Conditions Studied
Study Locations (5)
Arkansas
- Arkansas Children's Hospital - Little Rock
Florida
- UF CRC - Clinical Research Center - Gainesville
Michigan
- University of Michigan Hospital and Health Systems - Ann Arbor
Hampshire
- Haemophilia, Haemostasis & Thrombosis Centre - Basingstoke
Other
- Manchester Haemophilia Comprehensive Care Center - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-01 |
| Est. Completion | 2021-11-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02971969
The ClinicalTrials.gov registry entry for NCT02971969 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 20 other Hemophilia B trials with a reported enrollment target (94% lower). The listed sponsor is Ultragenyx Pharmaceutical, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophilia B appearing as the primary indexed condition, and to 0 interventions.
NCT02971969 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arkansas, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT02971969 about?
NCT02971969 is a clinical study titled "Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B". A long-term follow-up study to evaluate the safety, tolerability, and efficacy of DTX101 in adult males with moderate/severe to severe hemophilia B.
What is the current status of trial NCT02971969?
This trial is currently completed. The enrollment target is 6 participants. The study started on 2017-01. Estimated completion is 2021-11-06.
What conditions does trial NCT02971969 study?
This clinical trial studies the following conditions: Hemophilia B.
Who is sponsoring clinical trial NCT02971969?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02971969 being conducted?
This trial has 5 study locations across Arkansas, Florida, Michigan, Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RECRUITING · Phase 3
-
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
RECRUITING · Phase 1
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
RECRUITING · Phase 3
-
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.